Stock

Moderna secures tender to supply COVID-19 vaccine in EU, Norway, and North Macedonia

Investing.com — Moderna , Inc. (NASDAQ:MRNA) today confirmed that it has won a tender to supply its mRNA COVID-19 vaccine in the European Union (EU), Norway, and North Macedonia. The agreement, valid for up to four years, allows 17 countries to access Moderna’s vaccine.

Chantal Friebertshäuser, Senior Vice President, General Manager – Europe & Middle East, Moderna, stated that the agreement would enable Moderna to bolster national COVID-19 vaccination drives across the participating nations. She emphasized the importance of diverse supply sources and the availability of various vaccine formats like prefilled syringes to improve vaccination rates and campaign efficiency, ultimately reinforcing health security.

The agreement permits Moderna to supply its COVID-19 vaccine in various formats, including prefilled syringes. This format is favored by healthcare providers as it can reduce the risk of administration mistakes and save time, potentially enhancing the efficiency of vaccination campaigns.

In September 2024, the European Commission (EC) authorized the marketing of an updated version of Moderna’s COVID-19 mRNA vaccine Spikevax. This new formulation targets the SARS-CoV-2 variant JN.1 and is designed for active immunization to prevent COVID-19 in individuals aged six months and older.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com

    Fill Out & Get More Relevant News

    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.